<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00619268</url>
  </required_header>
  <id_info>
    <org_study_id>TORAVA</org_study_id>
    <secondary_id>ET2007-035</secondary_id>
    <nct_id>NCT00619268</nct_id>
  </id_info>
  <brief_title>Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma</brief_title>
  <acronym>TORAVA</acronym>
  <official_title>Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel® (Temsirolimus) and Avastin® (Bevacizumab) Versus Sutent® (Sunitinib) and Versus a Combination of Avastin® (Bevacizumab) and Roféron® (Interferon Alpha-2a) in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TORAVA trial is designed to evaluate the progression-free rate at 48 weeks of a
      combination of Torisel® and Avastin® given at first-line treatment in patients with
      metastatic renal cancer.

      Eligible patients will be randomly assigned, in a 2:1:1 ratio, to either Avastin® + Torisel®,
      or Sutent® or IFN+Avastin®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, open label, randomized, parallel group, multicenter study evaluating
      first-line treatment of patients with metastatic renal cancer using a combination of Torisel®
      administered intravenously as 25 mg every week and Avastin® administered intravenously as 10
      mg/kg every 2 weeks.

      Two standard arms with either Sutent® (given orally as 50 mg once daily during 4 weeks,
      followed by 2 weeks off) or a combination of Avastin® (administered intravenously as 10 mg/kg
      every 2 weeks) and Interferon (IFN, administered subcutaneously as 9 MU three times a week)
      will be used to validate the results obtained in the experimental arm (randomization
      eliminates selection biases), and to assess Sutent® efficacy rate on a more representative
      population than in Motzer's trial (Motzer NEJM 2007).

      The study is not designed to provide head-to-head comparisons between the experimental arm
      (Avastin® + Torisel®) and the two standard arms (Sutent® and IFN + Avastin®). Randomization
      will be used as a tool for allocating patients evenly into the 3 treatment arms to ensure
      proper balance of prognostic factors. If the progression-free rates observed in randomly
      assigned control patients are inconsistent with historical data, it may be a warning that the
      results observed for the experimental arm should be viewed with caution. Patients will be
      randomly assigned to either option in a 2:1:1 ratio (half less patients in the standard arms
      used only as historical comparators), and stratified according to inclusion center and
      performance status (ECOG PS 0 vs. 1 vs. 2).

      In the absence of severe toxicity, treatment will be continued until documented progression
      of the disease (RECIST criteria). Toxicity will be evaluated throughout the treatment period
      and until disappearance or stabilization of the side effect(s). In case of progression, each
      investigator makes his/her own treatment decisions, provided that all anti-cancer treatments
      given to the patients within the frame of the study are reported, as well as their results.

      Response rates will be assessed between weeks 11-12, 23-24, 35-36, 47-48 in the first year
      (corresponding to 2 cycles of Sutent®) and every 3 months afterwards until treatment stop, or
      until patient death or end of clinical data collection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free rate</measure>
    <time_frame>at 48 weeks post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate:efficacity</measure>
    <time_frame>Every 12 weeks during 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>at week 2, week 5-6 and after every 5-6 weeks during 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>at inclusion, month 6 and at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival and overall survival</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>25 mg once per week administered intravenously</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Torisel®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10 mg/kg * 1 time /2 weeks administered intravenously</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>Avastin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Sutent®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alpha-2a</intervention_name>
    <description>Administered subcutaneously as 9 MU three times per week</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Roféron®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients&gt;= 18 years of age;

          -  Patients with histological or cytological evidence of metastatic renal cell carcinoma
             mostly of all type,except for papillary;

          -  No prior systemic treatment (chemotherapy, immunotherapy, anti-angiogenic drugs, or
             treatment under evaluation) for metastatic renal cancer;

          -  No brain metastases revealed by MRI or CT-scan within 28 days prior to randomization.
             Patients with a history of brain metastases treated by surgery +/- radiation therapy
             can be included if they have normal brain MRI;

          -  E.C.O.G performance status =&lt;2;

          -  At least one measurable lesion using the RECIST criteria;

          -  Blood tests and renal and liver functions in the normal range with, in the 7 days
             prior to study entry, blood or serum values as follows:

        Hemoglobin &gt; 8g/dl; Neutrophil count &gt; 1500*10exp9/L; Platelets &gt; 100*10exp9/L; Serum
        creatinine &lt; 200µmol/L; Total Bilirubin &lt; 1.5 times upper limit of normal; ALT and AST &lt;
        2.5 times upper limit of normal or &lt; 5 ULN for patients with liver metastases, PT or INR &lt;
        1.5 times upper limit of normal in the absence of anticoagulant therapy;

          -  Absence of proteinuria confirmed by urinary dipstick test

          -  Fertile women must use effective means of contraception

          -  Mandatory affiliation with a healthy security insurance

          -  Signed written informed consent.

        Exclusion Criteria:

          -  Patient with pure papillary renal cell carcinoma

          -  Prior systemic treatment for metastatic renal cancer

          -  History of other malignancies, other than curatively treated in-situ carcinoma of the
             cervix or basal cell carcinoma of the skin, or any other curatively treated cancer
             with no sign of recurrence within 5 years prior to randomization

          -  Evidence of brain metastasis by computerized tomographic scan or MRI in the 28 days
             prior to randomization. Patients with history of brain metastases treated by exclusive
             brain therapy are not allowed to participate, even if brain MRI is normal

          -  Significant cardiovascular disease or uncontrolled hypertension while receiving
             appropriate medication (&gt;= 160 mm Hg systolic and/or &gt;= 90 mm Hg diastolic)

          -  Hepatic affection like chronic advanced hepatitis, liver cirrhosis or chronic
             hepatitis recently treated or in process of treatment by immunosuppressive agents,
             hepatitis auto-immune or history of auto-immune disease

          -  Major surgical procedure, open biopsy, or serious non healing wound within 28 days
             prior to randomization

          -  Uncontrolled hypercalcemia while receiving appropriate treatment

          -  Uncontrolled hypercholesterolemia or hypertriglyceridemia

          -  Patient under anti-vitamin K therapy

          -  Patient under strong CYP3A4 inhibitors

          -  Patient with severe neuropsychiatric disorder (or comitial crises)

          -  Patient included in another clinical trial, except for supportive care trials

          -  Pregnant or lactating women (mandatory negative serum or urinary pregnancy test at
             study entry for all women of childbearing potential)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie NEGRIER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard ESCUDIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux - Hôpital St André</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire DUPUTRYEN</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universiariare Lyon, Hôpital Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Valdegour-Centre médical Oncogard</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Hôpital Saint Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Val de Grâce</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospilier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Starsbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital FOCH</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):125-34. Erratum in: N Engl J Med. 2007 Jul 12;357(2):203.</citation>
    <PMID>17215530</PMID>
  </reference>
  <reference>
    <citation>Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-24.</citation>
    <PMID>17215529</PMID>
  </reference>
  <reference>
    <citation>Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 May 31;356(22):2271-81.</citation>
    <PMID>17538086</PMID>
  </reference>
  <results_reference>
    <citation>Négrier S, Gravis G, Pérol D, Chevreau C, Delva R, Bay JO, Blanc E, Ferlay C, Geoffrois L, Rolland F, Legouffe E, Sevin E, Laguerre B, Escudier B. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011 Jul;12(7):673-80. doi: 10.1016/S1470-2045(11)70124-3. Epub 2011 Jun 12.</citation>
    <PMID>21664867</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2008</study_first_submitted>
  <study_first_submitted_qc>February 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2008</study_first_posted>
  <last_update_submitted>February 14, 2013</last_update_submitted>
  <last_update_submitted_qc>February 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Temsirolimus</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Metastatic renal cell carcinoma</keyword>
  <keyword>Non-progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

